Updates and Statements

03.06.2025

Pfizer Announces New Chief Internal Medicine Officer

03.03.2025

Pfizer’s ABRYSVO® Receives Positive CHMP Opinion for Adults Aged 18 to 59

02.24.2025

Pfizer Announces New Chief Medical Officer

02.05.2025

Pfizer Announces New Chief Oncology Officer

01.17.2025

The Pfizer Foundation Provides $15 Million Investment to Improve Breast Cancer Care in Sub-Saharan Africa

09.20.2024

Pfizer Receives Positive CHMP Opinion for its Treatment for Adults and Adolescents with Hemophilia A and B

08.15.2024

Pfizer Statement on Publication of ELIQUIS® Maximum Fair Price

05.31.2024

Pfizer Receives Positive CHMP Opinion for its One-Time Gene Therapy for Adults with Hemophilia B

05.28.2024

Pfizer Reiterates Commitment to Pandemic Preparedness

05.21.2024

Hospira Inc. Issues A Voluntary Nationwide Recall For Buprenorphine Hydrochloride Injection Carpuject™ Units and Labetalol Hydrochloride Injection, USP Carpuject™ Units Due To The Potential For Incomplete Crimp Seals

03.22.2024

Pfizer Receives Positive CHMP Opinion for its Novel Antibiotic Combination for the Treatment of Patients with Multidrug-Resistant Infections and Limited Treatment Options

02.06.2024

Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer